Beats my expectations which were tempered by the EU MDR...

Beats my expectations which were tempered by the EU MDR transition. Osteopore has completed that whilst still raising revenues as it did so and as it pointed out:

"only 12.7% of certificates transitioned by the end of 2022"

Not only do their European sales resume, they do so in choked mkt supply = opportunities for increase revenue growth

I am baffled people are selling this stock under the raise price. Such is capital liquidity at the micro cap end of the market right now.

Management were idiots running the balance sheet so dry so late in the day, but the products are undeniably enthralling and revenue growth reemerging. Lets hope to see those margin improvements come through on the vertical integration (distribution) purchase and OSX starts to at least show promise of significantly reducing cash burn via meaningful gross profits at the top end of the income statement, to cover those too heavy costs in the lower portion.